UPDATE: Raymond James Lowers Gilead Target From $90 To $85 As Firm Notes 'Gilead's Phase 3 trial in F4 NASH patients (STELLAR4) failed' And Firm Has 'very little reason to suspect STELLAR3 in F3 NASH (data 2Q19E) will be any different'